-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana FY25 net loss widens to USD 18.4 million; R&D expense rises to USD 10.28 million

PUBT·05/01/2026 21:02:16
Listen to the news
Tiziana FY25 net loss widens to USD 18.4 million; R&D expense rises to USD 10.28 million
  • Tiziana Life Sciences posted a net loss of USD 18.4 million for fiscal 2025.
  • Revenue remained at no revenue from product sales.
  • Operating loss widened to USD 21.13 million.
  • Research and development expense climbed to USD 10.28 million.
  • January 2026 best-efforts registered direct offering raised gross proceeds of USD 8.8 million, with net proceeds of about USD 8.6 million earmarked to complete Phase 2a trials in na-SPMS and MSA through topline readouts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-051015), on May 01, 2026, and is solely responsible for the information contained therein.